Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

ENA-001

From Wikipedia, the free encyclopedia
(Redirected fromGAL-021)
Chemical compound
Pharmaceutical compound
ENA-001
Clinical data
Routes of
administration		IV
ATC code
  • None
Legal status
Legal status
Identifiers
  • 2-[(N-Methyl-N-methoxy)amino]-4,6-bis(propylamino)-1,3,5-triazine
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC11H22N6O
Molar mass254.338 g·mol−1
3D model (JSmol)
  • CCCNc1nc(nc(N(C)OC)n1)NCCC
  • InChI=1S/C11H22N6O/c1-5-7-12-9-14-10(13-8-6-2)16-11(15-9)17(3)18-4/h5-8H2,1-4H3,(H2,12,13,14,15,16)
  • Key:FJNLCHNQVJVCPY-UHFFFAOYSA-N

ENA-001 (formerlyGAL-021)[1] is a drug related toalmitrine which acts as arespiratory stimulant, with its mechanism of action primarily thought to involve blocking theBKCapotassium channel,[2] although secondary mechanisms may also be involved.[3] It was developed byGalleon Pharmaceuticals, and is being tested inclinical trials for potential uses inpost-operative care,[4] as well as more generally to counteract therespiratory depression which can be a side effect ofopioidanalgesic drugs.[5][6][7]

See also

[edit]

References

[edit]
  1. ^Miller TL, Raab LM, Shaffer TH, Schweikert A, Diana F, Fort P, et al. (September 2022)."A Novel Agnostic Respiratory Stimulant as a Treatment for Apnea of Prematurity: A Proof-of-Concept Study".Cureus.14 (9): e28900.doi:10.7759/cureus.28900.PMC 9544529.PMID 36237747.S2CID 252141895.
  2. ^McLeod JF, Leempoels JM, Peng SX, Dax SL, Myers LJ, Golder FJ (November 2014)."GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers".British Journal of Anaesthesia.113 (5):875–883.doi:10.1093/bja/aeu182.PMID 24989775.
  3. ^Baby SM, Hoshi T, Peng S, Dax SL, Golder FJ, MacIntyre DE, Mannion JC (2012)."Comparison of the respiratory effects of GAL-021 in BK α subunit knockout (Slo1−/−) and wild-type mice".The FASEB Journal.26 (1 Supplement): 704.30.doi:10.1096/fasebj.26.1_supplement.704.30.
  4. ^Golder FJ, Hewitt MM, McLeod JF (November 2013)."Respiratory stimulant drugs in the post-operative setting".Respiratory Physiology & Neurobiology.189 (2):395–402.doi:10.1016/j.resp.2013.06.010.PMID 23791825.S2CID 2558991.
  5. ^Baby SM, Gruber RB, Puskovic V, Peng S, Dax SL, Golder FJ, MacIntyre DE, Mannion JC (2012)."GAL-021, a novel respiratory stimulant, attenuates opioid–induced respiratory depression without compromising analgesia".The FASEB Journal.26 (1 Supplement): 704.28.doi:10.1096/fasebj.26.1_supplement.704.28.
  6. ^van der Schier R, Roozekrans M, van Velzen M, Dahan A, Niesters M (4 September 2014)."Opioid-induced respiratory depression: reversal by non-opioid drugs".F1000Prime Reports.6: 79.doi:10.12703/P6-79.PMC 4173639.PMID 25343036.
  7. ^Roozekrans M, van der Schrier R, Okkerse P, Hay J, McLeod JF, Dahan A (September 2014)."Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers".Anesthesiology.121 (3):459–468.doi:10.1097/ALN.0000000000000367.PMID 25222672.S2CID 35738816.
Otherrespiratory system products (R07)
Lung surfactants
Respiratory stimulants
5-HT4 receptor agonists
Other agents for treating respiratory depression
Stub icon

Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ENA-001&oldid=1194023737"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp